Covered Call Analyzer AGGRESSIVE "STOCKS-TO-CONSIDER"
for November, 2004
|
Company Name |
Stock Symbol |
Stock Price |
# of shares |
Total Cost* |
Option Symbol |
Dec Option Price |
Income from sale* |
Strike Price |
Projected return if Called after one month* |
Actual $ return* |
Actual % Return* |
Enzon Pharma. | ENZN | $14.79 | 600 | $8,894 | QYZLW | $0.90 | $520 | 17.5 | 29% | ($700) | -8% |
| Comments: |
Not called. Sold Jan17.5 at 0.30. Not called. Sold all shares at $12.49 to close out position. |
||||||||||
| Nectar Theraputics | NKTR | $15.09 | 600 | $9,074 | QNXLW | $0.75 | $430 | 17.5 | 25% | +$1,856 | +20% |
| Comments: |
Called. |
||||||||||
| Cyberonics, Inc. | CYBX | $19.99 | 400 | $8,016 | QAJLX | $0.90 | $340 | 22.5 | 20% | +$2,024 | +25% |
| Comments: |
Not called. Sold Jan22.5 at 1.80. Called. |
||||||||||
| Netflix, Inc. | NFLX | $11.24 | 800 | $9,012 | QNQLS | $0.55 | $420 | 12.5 | 19% | +$1,408 | +16% |
| Comments: |
Called. |
||||||||||
| Rambus, Inc. | RMBS | $20.73 | 400 | $8,312 | BNQLX | $1.05 | $400 | 22.5 | 16% | +$1,088 | +13% |
| Comments: |
Called. |
||||||||||
| Omnivision Tech. | OVTI | $18.26 | 500 | $9,150 | UCMLD | $0.70 | $330 | 20 | 16% | ($755) | -8% |
| Comments: |
Not called. Sold Jan20 at 0.35. Not called. Sold all shares at $15.78 to close out position. |
||||||||||
| Ask Jeeves, Inc. | ASKJ | $23.75 | 400 | $9,520 | AUKLS | $1.30 | $500 | 25 | 12% | +$980 | +10% |
| Comments: |
Called. |
||||||||||
| Interdigital Comm. | IDCC | $19.17 | 500 | $9,605 | DAQLD | $1.05 | $505 | 20 | 11% | +$900 | +9% |
| Comments: |
Called. |
||||||||||
| American Pharma. | APPX | $29.08 | 300 | $8,744 | AQOLF | $1.70 | $490 | 30 | 10% | +$746 | +9% |
| Comments: |
Called. |
||||||||||
| Celgene Corp. | CELG | $26.80 | 300 | $8,060 | LQHLY | $1.35 | $385 | 27.5 | 9% | +$746 | +11% |
| Comments: |
Not called. Sold Jan27.5 at 1.20. Called. |
||||||||||
|
All positions closed out with portfolio value up +$8,463. |
|||||||||||
The stocks listed above are for illustrative and educational purposes only and should not be construed as an endorsement, recommendation, or solicitation to buy or sell any particular security.